Sarepta Therapeutics Inc (SRPT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.72B
Last updated: Nov 17, 2026 at 4:38 PM ET
Sarepta Therapeutics Inc (SRPT) Statistics
Sarepta Therapeutics (SRPT) has a market cap of $1.72B and an enterprise value of $2.11B. Its share count is up 5.68% from a year earlier. Revenue fell 18.95% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 22.32% above the market cap, as debt exceeds cash.
| Market Cap | $1.72B |
|---|---|
| Enterprise Value | $2.11B |
| Latest price (Nov 17, 2026) | $14.77 |
Key Dates
The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 23, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 0.8x and 1.0x. Its year-end P/S ranged from 1.0x to 276.4x from 2016 to 2025.
| Forward P/E | 5.5x |
|---|---|
| P/S Ratio | 0.8x |
| Forward P/S | 0.9x |
| P/B Ratio | 1.0x |
| P/FCF Ratio | 8.9x |
| P/OCF Ratio | 9.3x |
Enterprise Valuation
Counting debt and cash, the company is valued at 11.0x free cash flow.
| EV / Earnings | 142.8x |
|---|---|
| EV / Sales | 1.1x |
| EV / FCF | 11.0x |
Price Statistics
The stock is down 21.48% over 52 weeks and trades 19.38% below its 50-day average.
| Beta (1Y) | 1.74 |
|---|---|
| 52-Week Change | -21.48% |
| 1-Month Change | -16.69% |
| 3-Month Change | -25.14% |
| 6-Month Change | -11.24% |
| 5-Year Change | -76.47% |
| 10-Year Change | -52.55% |
| Total Return (1Y) | -21.48% |
| Total Return (3Y CAGR) | -43.78% |
| Total Return (5Y CAGR) | -28.85% |
| Return vs SPY (1Y) | -26.87% |
| Max Drawdown (1Y) | -38.02% |
| Max Drawdown (3Y) | -92.72% |
| Sharpe Ratio (1Y) | -0.24 |
| Correlation with SPY (1Y) | 0.35 |
| 50-Day Average | $18.32 |
| 200-Day Average | $18.46 |
| 52-Week Range | $14.68 to $24.68 |
| RSI (14 Days) | 31.2 |
| Average Volume (20 Days) | 1.82M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.46x current liabilities, and total debt is 0.56x shareholder equity.
| Current Ratio | 3.46x |
|---|---|
| Quick Ratio | 2.13x |
| Debt / Equity | 0.56x |
| Debt / FCF | 4.86x |
Returns and Efficiency
Return on invested capital is -3.22% over the last 12 months, against a 5-year average of -24.03%.
| Return on Equity (ROE) | 0.97% |
|---|---|
| Return on Assets (ROA) | 0.47% |
| Return on Invested Capital (ROIC) | -3.22% |
| ROE (5Y Average) | -67.48% |
| ROA (5Y Average) | -13.51% |
| ROIC (5Y Average) | -24.03% |
| Asset Turnover | 0.59x |
| Receivables Turnover | 5.24x |
Taxes
Income tax took 60.49% of pretax income over the last 12 months.
| Income Tax (TTM) | $22.60M |
|---|---|
| Effective Tax Rate | 60.49% |
Scores
SRPT has an Altman Z-Score of -0.34, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -0.34 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $1.96B over the last 12 months.
| Revenue | $1.96B |
|---|---|
| Revenue Growth (YoY) | -18.95% |
| Gross Profit | $1.96B |
| Operating Income | -$48.90M |
| Pretax Income | $37.36M |
| Net Income | $14.76M |
| Reported EPS (TTM) | -$0.10 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 48.26% of the $3.17B in total assets.
| Cash and Equivalents | $472.76M |
|---|---|
| Total Debt | $857.36M |
| Net Debt | $384.60M |
| Net Debt Per Share | $3.63 |
| Working Capital | $1.62B |
| Shareholder Equity | $1.53B |
| Book Value Per Share | $14.43 |
| Total Assets | $3.17B |
| Total Liabilities | $1.64B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $9.16M of capital spending, operating cash flow left $176.40M of free cash flow.
| Operating Cash Flow | $185.56M |
|---|---|
| Capital Expenditures | $9.16M |
| Free Cash Flow | $176.40M |
| FCF Per Share | $1.67 |
| Depreciation and Amortization | $32.16M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -2.50%, against a 5-year average of -32.97%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -2.50% |
| Pretax Margin | 1.91% |
| Net Margin | 0.75% |
| FCF Margin | 9.02% |
| Operating Margin (5Y Average) | -32.97% |
| Net Margin (5Y Average) | -39.65% |
Growth
Revenue grew 33.06% a year over 3 years.
| Revenue Growth (3Y CAGR) | +33.06% |
|---|---|
| Revenue Growth (5Y CAGR) | +32.41% |
| Book Value Per Share Growth (2Y CAGR) | +15.65% |
| Tangible Book Per Share Growth (2Y CAGR) | +15.65% |
Dividends and Yields
SRPT does not pay a dividend. Its free cash flow yield is 11.27%.
| FCF Yield | 11.27% |
|---|---|
| Buyback Yield | 0.01% |
| Shareholder Yield | 0.01% |
Stock Splits
The last split was a 1-for-6 reverse split on Jul 12, 2012.
| Last Split Date | Jul 12, 2012 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:6 |
Peer Position
Against 9 similar companies, SRPT has the lowest P/S.
P/S RatioPeer median 21.6x
ROICPeer median -65.35%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +56.18%
| P/S Ratio | 0.8x vs 21.6x median |
|---|---|
| ROIC | -3.22% vs -65.35% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -18.95% vs +56.18% median |
Analyst Forecast
Consensus estimates put revenue growth at -20.66% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -20.66% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About SRPT
What is SRPT's market cap?
Sarepta Therapeutics has a market cap of $1.72B. Its enterprise value, which adds debt and subtracts cash, is $2.11B.
How many shares of SRPT are outstanding?
Sarepta Therapeutics has 105.93M shares outstanding. The count is up 5.68% from a year earlier.
Does SRPT pay a dividend?
No. Sarepta Therapeutics does not pay a dividend.
How much debt does SRPT have?
Sarepta Therapeutics has $857.36M of total debt and $472.76M of cash and equivalents, a net debt position of $384.60M.
SRPT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors